VERTEX PHARMACEUTICALS INC MA
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the first quarter of 2024, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
| Name and Title | Date of Adoption of Trading Plan | Scheduled Expiration Date of Trading Plan (1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|
| E. Morrow "Morrey" Atkinson, IIIEVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations | 2/22/2024 | 2/28/2025 | 25,290(2) |
| Jonathan BillerEVP, Chief Legal Officer | 2/13/2024 | 4/30/2025 | 9,825(2) |
| Carmen BozicEVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer | 2/27/2024 | 1/31/2025 | 13,680 |
| Reshma KewalramaniChief Executive Officer and President | 2/7/2024 | 5/20/2025 | 96,388(2) |
| Ourania "Nia" TatsisEVP, Chief Regulatory and Quality Officer | 2/29/2024 | 5/1/2025 | 9,484(2) |
| Charles F. Wagner, Jr.EVP, Chief Financial Officer | 2/26/2024 | 1/31/2025 | 6,500 |
| Bruce SachsDirector | 2/12/2024 | 2/28/2025 | 12,368 |
| (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.